Skip to main content
Premium Trial:

Request an Annual Quote

Predicine, CloudHealth Launch Liquid Biopsy Tests in China

NEW YORK (GenomeWeb) – Predicine announced today that its next-generation sequencing-based liquid biopsy diagnostics for lung cancer and prostate cancer are the first tests to launch in China under a co-promotion deal with Shanghai-based CloudHealth Genomics.

In April, the companies announced that they had signed a deal under which CloudHealth will provide clinical genetic testing infrastructure and sequencing capacity in China for Predicine's PrediSeq cell-free DNA NGS cancer diagnostics. 

According to Predicine, its PrediSeq-Lung and PrediSeq-Prostate liquid biopsy tests are the first covered under the partnership, with additional tests for major cancer types planned to launch in China later this year.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.